Device Makers See Easier Approval Process Coming To Japan
This article was originally published in PharmAsia News
Executive Summary
Makers of medical devices anticipate quicker Japanese action on future approvals in the wake of recent moves by regulators. New reimbursement measures have been approved and recent trade talks indicate future slight changes in a product will not suffer the full approval process. Philip Agress, vice president of AdvaMed, said Japan now has the slowest approval process in the industrialized world and foreign companies have had to jump through more hoops than domestic makers. The Japanese market for medical devices, at $20 billion, is second only to that of the United States. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.